برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Lybalvi (olanzapine and samidorphan) Tablets Date of Approval: May 28, 2021 Company: Alkermes plc Treatment for: Schizophrenia, Bipolar Disorder Lybalvi (olanzapine and samidorphan) is a combination of an established antipsychotic agent (olanzapine) and a novel μ-opioid receptor antagonist (samidorphan) for the treatment of schizophrenia and bipolar I disorder. https://t.me/ppdprogram

➡️Zegalogue (dasiglucagon) Injection Date of Approval: March 22, 2021 Company: Zealand Pharma A/S Treatment for: Hypoglycemia Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older. https://t.me/ppdprogram

➡️Nasonex 24HR Allergy (mometasone furoate monohydrate) Nasal Spray Date of Approval: March 17, 2022 Company: Perrigo Company plc Treatment for: Allergic Rhinitis Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies. https://t.me/ppdprogram

➡️Hyftor (sirolimus) Topical Gel Date of Approval: March 22, 2022 Company: Nobelpharma America, LLC Treatment for: Facial Angiofibroma Associated with Tuberous Sclerosis Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. https://t.me/ppdprogram

➡️Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection Date of Approval: March 23, 2022 Company: Novartis Treatment for: Prostate Cancer Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). https://t.me/ppdprogram

➡️Opdualag (nivolumab and relatlimab-rmbw) Injection Date of Approval: March 18, 2022 Company: Bristol Myers Squibb Treatment for: Melanoma Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma. https://t.me/ppdprogram

➡️Ztalmy (ganaxolone) Oral Suspension Date of Approval: March 18, 2022 Company: Marinus Pharmaceuticals, Inc. Treatment for: CDKL5 Deficiency Disorder Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) https://t.me/ppdprogram

➡️Spikevax (Moderna COVID-19 Vaccine) (COVID-19 Vaccine, mRNA) Injection - formerly mRNA-1273 Date of Approval: January 31, 2022 Company: Moderna, Inc. Treatment for: Prevention of COVID-19 Spikevax (COVID-19 Vaccine, mRNA) is an mRNA vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. https://t.me/ppdprogram

➡️Vonjo (pacritinib) Capsules Date of Approval: February 28, 2022 Company: CTI BioPharma Corp. Treatment for: Myelofibrosis Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia. https://t.me/ppdprogram

➡️Pyrukynd (mitapivat) Tablets Date of Approval: February 17, 2022 Company: Agios Pharmaceuticals, Inc. Treatment for: Pyruvate Kinase Deficiency Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. https://t.me/ppdprogram

➡️Carvykti (ciltacabtagene autoleucel) Suspension for Intravenous Infusion Date of Approval: February 28, 2022 Company: Janssen Pharmaceutical Companies Treatment for: Multiple Myeloma Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma. https://t.me/ppdprogram

➡️Releuko (filgrastim-ayow) Injection Date of Approval: February 25, 2022 Company: Kashiv BioSciences, LLC Treatment for: Neutropenia Associated with Chemotherapy, Neutropenia Releuko (filgrastim-ayow) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions. https://t.me/ppdprogram

➡️Norliqva (amlodipine besylate) Oral Solution Date of Approval: February 24, 2022 Company: CMP Pharma, Inc. Treatment for: High Blood Pressure, Coronary Artery Disease, Angina Norliqva (amlodipine besylate) is an oral solution formulation of the approved calcium channel blocker amlodipine for the treatment of hypertension and angina in patients with coronary artery disease. https://t.me/ppdprogram

➡️Igalmi (dexmedetomidine) Sublingual Film Company: BioXcel Therapeutics, Inc. Date of Approval: April 5, 2022 Treatment for: Agitation Igalmi (dexmedetomidine) is a sublingual film formulation of the approved alpha2-adrenergic receptor agonist dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. https://t.me/ppdprogram

➡️Vijoice (alpelisib) Tablets Company: Novartis Pharmaceuticals Corporation Date of Approval: April 5, 2022 Treatment for: PIK3CA-Related Overgrowth Spectrum Vijoice (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. https://t.me/ppdprogram

➡️Alymsys (bevacizumab-maly) Injection Company: Amneal Pharmaceuticals LLC Date of Approval: April 13, 2022 Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer. https://t.me/ppdprogram

➡️Epsolay (benzoyl peroxide) Cream Company: Sol-Gel Technologies, Ltd. Date of Approval: April 22, 2022 Treatment for: Rosacea Epsolay (benzoyl peroxide) is a topical oxidizing agent for the treatment of inflammatory lesions of rosacea in adults. https://t.me/ppdprogram

➡️Vivjoa (oteseconazole) Capsules Company: Mycovia Pharmaceuticals, Inc. Date of Approval: April 26, 2022 Treatment for: Vaginal Yeast Infection Vivjoa (oteseconazole) is an oral azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. https://t.me/ppdprogram

➡️Cuvrior (trientine tetrahydrochloride) Tablets Company: Orphalan SA Date of Approval: April 28, 2022 Treatment for: Wilson's Disease Cuvrior (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. https://t.me/ppdprogram

➡️Camzyos (mavacamten) Capsules Company: Bristol-Myers Squibb Company Date of Approval: April 28, 2022 Treatment for: Hypertrophic Cardiomyopathy Camzyos (mavacamten) is a first-in-class cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. https://t.me/ppdprogram